Blow-Fill-Seal Machine Designed for Development or Low-Output Production
The Asep-Tech Lab+ Blow-Fill-Seal Machine from Weiler Engineering is a compact, laboratory-sized machine with many of the same options that are available on Weiler’s full-scale production machine.
Asep-Tech Lab+ Blow-Fill-Seal Machine. Courtesy Weiler Engineering.
The Asep-Tech Lab+ Blow-Fill-Seal Machine from Weiler Engineering is a compact, laboratory- sized machine suited to meet the recent demand for low-output production of pharmaceutical products and/or small-development batches using this advanced aseptic technology. The design meets the needs for bio/pharmaceutical applications including biologics, 503B drug shortages, stability testing, clinical trials, and high-value batches.
Blow-fill-seal technology is known for the production of shatterproof, durable, aseptically-packaged products in one uninterrupted operation. The modularity of the laboratory-sized platform allows Weiler to offer a variety of options such as single-use technology or conventional clean-in-place and steam-in-place technologies; a new, patent-pending grade-A filling zone; a new, patent-pending particulate matter removal system for when the hot knife is in use; a 21 CFR Part 11-compliant audit trail; fully integrated supervisory control and data acquisition capabilities; automated onboard deflashing; insertion of rubber stoppers or tip/cap inserts; and other items Weiler currently offers on all full-scale production machines. The machine was designed for ease of changeover and product-range flexibility.
Source: Weiler
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
